While this was not a randomized controlled trial, Novo said the findings provide evidence that the heart-protective benefits of Wegovy and its main ingredient semaglutide may not be the same for all ...

Novo Nordisk (NVO) stock in focus as its obesity drug Wegovy outperforms Eli Lilly's (LLY) rival Zepbound in reducing serious ...

Hims & Hers looks undervalued with 88% YoY growth, ZAVA scaling, and solid support near $41, despite risks and high short interest. Learn why HIMS stock is a buy.

Novo Nordisk A/S (NYSE:NVO) is a discover, developer, and marketer of pharmaceutical products, particularly for diabetes care.

Eli Lilly's retatrutide is still in clinical trials. But gym bros are already using a version of the weight-loss drug, amid a growing DIY culture in fitness circles.

Novo Nordisk alone contributing one-fifth of employment gains to Denmark. But economic headwinds are mounting.

Novo Nordisk’s blockbuster obesity drug Wegovy is set to be greeted by physician enthusiasm and "swift" adoption as it taps into a new liver disease market in the U.S. | Wegovy's mechanism of action ...

Ozempic and Wegovy maker Novo Nordisk stock is down 35% in 2025. The country also said Trump tariffs were hitting the economy ...

In December 2024, Teva also secured FDA approval for the other liraglutide brand Victoza, indicated for type 2 diabetes.

The FDA has approved the first generic GLP-1 specifically indicated for weight loss, according to a press release from Teva Pharmaceuticals. As Healio previously reported, Teva Pharmaceuticals ...

Denmark cuts 2025 growth forecast as Novo Nordisk slowdown and US tariffs raise fears of over-reliance on pharma.